Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2020-04-15 Capital/Financing Update
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 13, 2020, reporting the entry into a material definitive agreement, specifically an Equity Distribution Agreement for an at-the-market equity offering. The content focuses on the terms of this financing agreement, including commission rates and termination conditions. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The primary subject is a capital raising activity through an equity distribution agreement. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length is 6762 characters, which is sufficient to contain substantive details about the financing agreement rather than just an announcement or notice. Hence, the classification is CAP with high confidence.
2020-04-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an 'at-the-market' offering of common stock. It includes detailed information about the offering, sales agent, use of proceeds, risk factors, and legal matters. The document is a formal disclosure related to capital raising activities and is not a financial report, earnings release, or management discussion. It is a regulatory filing specifically for a capital raising event under securities laws. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive filing about financing.
2020-04-14 English
FORM 10-Q
Interim / Quarterly Report Q2 2020
2020-04-13 English
Regulatory Filings 2020
Regulatory Filings
2020-04-13 English
Regulatory Filings 2020
Regulatory Filings
2020-04-07 English
POS AM
Capital/Financing Update Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, related to the offering of shares and warrants by Artelo Biosciences, Inc. It includes detailed information about the securities offering, company overview, risk factors, management discussion, and other prospectus elements. The document is a registration statement amendment for securities issuance, which is a capital raising activity. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and securities offering details. It is not an annual report, earnings release, or other report type, but specifically a registration statement amendment related to capital raising.
2020-04-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.